In the battle against patient overdose, Toshiba America Medical Systems brought two weapons to RSNA 2010. One is its Adaptive Iterative Dose Reduction (AIDR), software similar in approach to products from competing CT vendors who use iterative reconstruction to squeeze noise out of their images. The other, Target CTA, is a dose protocol devised specifically for cardiac scans done on the Aquilion One.
In the battle against patient overdose, Toshiba America Medical Systems brought two weapons to RSNA 2010. One is its Adaptive Iterative Dose Reduction (AIDR), software similar in approach to products from competing CT vendors who use iterative reconstruction to squeeze noise out of their images. The other, Target CTA, is a dose protocol devised specifically for cardiac scans done on the Aquilion One.
AIDR made a cameo appearance at the RSNA meeting last year, when it was discussed but not described at any length. It has recently received 510(k) clearance from the FDA and Toshiba is claiming AIDR can achieve dose reductions of as much as 75%.
The new cardiac dose protocol, Target CTA, is a commercial product but designed for use only on patients, including pediatric ones, with stable heart rates. The protocol tailors exposure, which on the Aquilion One is accomplished in a single rotation of the gantry, thanks to the onboard 16-cm-wide detector.
With Target CTA, operators more accurately target the heart, according to Toshiba and, thereby, minimize padding of the scan range that leads to increased patient dose. Used with Toshiba’s advanced SURECardio Prospective, which can reduce radiation dose by up to 80%, Target CTA can lower radiation by another 20%, according to the company.
AI Facilitates Nearly 83 Percent Improvement in Turnaround Time for Fracture X-Rays
December 19th 2023In addition to offering a 98.5 percent sensitivity rate in diagnosing fractures on X-ray, an emerging artificial intelligence (AI) software reportedly helped reduce mean turnaround time on X-ray fracture diagnosis from 48 hours to 8.3 hours, according to new research presented at the Radiological Society of North America (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.